Research Article Details

Article ID: A11094
PMID: 31045630
Source: Eur J Gastroenterol Hepatol
Title: Comparison of anthropometric measurements for prediction of the atherosclerosis and liver histology in young adults with nonalcoholic fatty liver disease.
Abstract: AIM: Anthropometry is a good evaluation tool that establishes the association between body fat distribution and metabolic risk factors precisely. The aim of this study was to test the association of anthropometric measurements with subclinical atherosclerosis and liver fibrosis. METHODS: A total of 78 patients with nonalcoholic fatty liver disease (NAFLD) patients who had no known cardiovascular disease risk factors and 26 volunteered healthy controls were enrolled. Patients with suspected fatty liver underwent a liver biopsy. BMI, waist circumference (WC), hip circumference, and neck circumference (NC) were measured. To detect the presence of subclinical atherosclerosis, carotid intima-media thickness and carotid-femoral pulse wave velocity (cf-PWV) were examined. RESULTS: NAFLD patients with fibrosis had higher NC, WC, and hip circumference levels, but no difference was observed between NAFLD patients without fibrosis and controls in these parameters. BMI was statistically different among the three groups (P < 0.05). After adjusting for confounding risk factors, the only significant parameter associated with histologic severity of NAFLD was WC, with odds ratio of 1.10. All anthropometric measurements were correlated positively with fibrosis, cf-PWV, and each other. While the association between BMI and cf-PWV remained significant, WC was found to be an independent risk factor for carotid intima-media thickness after adjustment of known cardiovascular risk factors. CONCLUSION: WC is the strongest predictor of liver fibrosis as the anthropometric indexes in patients with NAFLD. NC can be used as an additional useful screening test for the primary evaluation of patients with NAFLD, even if it is not an independent risk factor.
DOI: 10.1097/MEG.0000000000001431

Strategy ID Therapy Strategy Synonyms Therapy Targets Therapy Drugs
S03 Anti-fibrosis fibrosis Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 Details

Target ID Target Name GENE Action Class UniProtKB ID Entry Name

Diseases ID DO ID Disease Name Definition Class
I14 9970 Obesity An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition Details
I07 1936 Arteriosclerosis Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C35768 disease of anatomical entity/cardiovascular system disease/ vascular disease/ artery disease Details

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D080 Citrulline Chemical drug DB00155 -- -- Under clinical trials Details
D328 Serine Chemical drug DB00133 SRR Improve insulin resistance Under clinical trials Details
D094 Cysteamine Chemical drug DB00847 GSS stimulant Renal drug Under clinical trials Details
D095 Cysteamine bitartrate Chemical drug DB00847 -- -- Under clinical trials Details